Kilitch Drugs (India) Ltd's Q3FY25 Quarter Results
- 12 Feb 2025
Result Summary
- Kilitch Drugs (India) Ltd reported a 10.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 66.6%.
- Its expenses for the quarter were up by 17.4% QoQ and 55.5% YoY.
- The net profit decreased 34.8% QoQ and increased 222.4% YoY.
- The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 3.7 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 57.89 | 52.64 | 34.75 | 10.0% | 66.6% |
Total Expenses | 49.64 | 42.29 | 31.92 | 17.4% | 55.5% |
Profit Before Tax | 8.25 | 10.35 | 2.82 | -20.3% | 192.6% |
Tax | 2.64 | 1.73 | 1.08 | 52.6% | 144.4% |
Profit After Tax | 5.61 | 8.61 | 1.74 | -34.8% | 222.4% |
Earnings Per Share | 3.70 | 5.40 | 1.90 | -31.5% | 94.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Kilitch Drugs (India) Ltd is a prominent player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of pharmaceutical products. The company primarily focuses on producing injectable formulations and is known for its sterile liquid products. Kilitch Drugs caters to both domestic and international markets, providing a wide range of therapeutic solutions. The company has shown significant growth over the years, underpinned by its commitment to quality and innovation. However, there is no specific information available about any recent major developments or strategic changes within the company based on the data provided.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Kilitch Drugs (India) Ltd reported a total income of ₹57.89 crores. This represents a quarter-over-quarter (QoQ) increase of 10.0% from ₹52.64 crores in the previous quarter (Q2FY25). Year-over-year (YoY), the company's total income witnessed a substantial growth of 66.6% compared to ₹34.75 crores in the third quarter of the fiscal year 2024 (Q3FY24). The notable increase in revenue on both a quarterly and yearly basis suggests a robust expansion in the company's business activities and sales performance.
Profitability
For Q3FY25, Kilitch Drugs (India) Ltd recorded a profit before tax of ₹8.25 crores, which is a decrease of 20.3% QoQ from ₹10.35 crores in Q2FY25. Despite this decline on a quarterly basis, the company experienced a significant YoY growth of 192.6% from ₹2.82 crores in Q3FY24. The tax expense for the current quarter was ₹2.64 crores, marking an increase of 52.6% QoQ and 144.4% YoY. Consequently, the profit after tax for Q3FY25 was ₹5.61 crores, reflecting a decrease of 34.8% QoQ from ₹8.61 crores but an impressive YoY growth of 222.4% from ₹1.74 crores. Earnings per share for Q3FY25 stood at ₹3.70, down by 31.5% QoQ from ₹5.40 but up by 94.7% YoY from ₹1.90.
Operating Metrics
Analyzing the operating metrics, total expenses for Kilitch Drugs (India) Ltd in Q3FY25 amounted to ₹49.64 crores, which indicates a 17.4% increase QoQ from ₹42.29 crores in Q2FY25. On a YoY basis, the expenses rose by 55.5% from ₹31.92 crores in Q3FY24. The increase in expenses is notable and reflects the company's operational scaling. Despite the rise in expenses, the company's revenue growth outpaced the increase in expenses on both a quarterly and yearly basis. This dynamic has implications for the company's operational efficiency and cost management strategies. The financial data provided does not include specific metrics such as P/E ratio, debt-to-equity ratio, or current ratio, limiting further analysis of operational efficiency or financial stability.
